USING A DISCRETE CHOICE EXPERIMENT TO EXPLORE PERIOPERATIVE TREATMENT PREFERENCES IN GASTRIC AND GASTROESOPHAGEAL CANCER
Author(s)
Vishal Patel, MSc1, Anuj Shah, PhD2, Will King, MPH3, Sarah R. Hill, PhD3, Yemi Oluboyede, MSc, PhD3.
1AstraZeneca, Cambridge, United Kingdom, 2AstraZeneca, Gaithersburg, MD, USA, 3Putnam, Newcastle upon Tyne, United Kingdom.
1AstraZeneca, Cambridge, United Kingdom, 2AstraZeneca, Gaithersburg, MD, USA, 3Putnam, Newcastle upon Tyne, United Kingdom.
OBJECTIVES: This study aims to assess patients’ and physicians’ preferences for perioperative treatments for gastric cancer (GC) and gastroesophageal junction cancer (GEJC). Limited evidence exists regarding perioperative treatment preferences among patients or treating physicians. By eliciting these preferences, the study seeks to provide insights that can support shared decision-making in the perioperative management of stomach cancer.
METHODS: A discrete choice experiment (DCE) was conducted to explore patients’ and physicians' preferences for various perioperative treatment characteristics. The design of the DCE was informed by qualitative interviews with a sample of patients and physicians. Six treatment attributes were included in the DCE: recurrence-free survival, complications from surgery, treatment tolerability (leading to treatment discontinuation), lifestyle changes, treatment frequency, and treatment duration. Discrete choice models were estimated to quantify treatment preferences and relative attribute importance (RAI) for both patients and physicians.
RESULTS: Two-hundred patients and 150 physicians were included in the DCE analysis. Data quality was very good with less than 2% of the sample failing a dominance test designed to assess respondent engagement and logical consistency in the DCE tasks. Among patients, treatment tolerability and recurrence-free survival were considered the most important attributes (RAI: 33.7% and 27.8%), while treatment frequency and treatment duration were considered less important (RAI: 2.4% and 7.7%). Patients’ and physicians' preferences were broadly comparable, though patients valued treatment tolerability and lifestyle changes slightly higher than physicians.
CONCLUSIONS: Patients with GC/GEJC and physicians prioritise treatment tolerability and recurrence-free survival over lifestyle changes, treatment duration, and treatment frequency. These findings could indicate that patients and physicians favour more intensive treatments, which provide greater improvement in clinical outcomes, despite their impact on lifestyle changes, risk of surgical complications, and treatment duration or frequency. These findings can inform future treatment development and support shared decision-making in the management of GC/GEJC.
METHODS: A discrete choice experiment (DCE) was conducted to explore patients’ and physicians' preferences for various perioperative treatment characteristics. The design of the DCE was informed by qualitative interviews with a sample of patients and physicians. Six treatment attributes were included in the DCE: recurrence-free survival, complications from surgery, treatment tolerability (leading to treatment discontinuation), lifestyle changes, treatment frequency, and treatment duration. Discrete choice models were estimated to quantify treatment preferences and relative attribute importance (RAI) for both patients and physicians.
RESULTS: Two-hundred patients and 150 physicians were included in the DCE analysis. Data quality was very good with less than 2% of the sample failing a dominance test designed to assess respondent engagement and logical consistency in the DCE tasks. Among patients, treatment tolerability and recurrence-free survival were considered the most important attributes (RAI: 33.7% and 27.8%), while treatment frequency and treatment duration were considered less important (RAI: 2.4% and 7.7%). Patients’ and physicians' preferences were broadly comparable, though patients valued treatment tolerability and lifestyle changes slightly higher than physicians.
CONCLUSIONS: Patients with GC/GEJC and physicians prioritise treatment tolerability and recurrence-free survival over lifestyle changes, treatment duration, and treatment frequency. These findings could indicate that patients and physicians favour more intensive treatments, which provide greater improvement in clinical outcomes, despite their impact on lifestyle changes, risk of surgical complications, and treatment duration or frequency. These findings can inform future treatment development and support shared decision-making in the management of GC/GEJC.
Conference/Value in Health Info
2026-05, ISPOR 2026, Philadelphia, PA, USA
Value in Health, Volume 29, Issue S6
Code
PCR14
Topic
Patient-Centered Research
Disease
SDC: Oncology